Targeted Therapy for the Central Nervous System: Formulation, Clinical Challenges, and Regulatory Strategies presents research on various delivery methods of drugs to the central nervous system and brain. This volume examines targeted therapies for neurodegenerative disorders and succinctly outlines the future of drug delivery systems, highlighting significant advancements specifically relating to central nervous system delivery. This book will be of great interest to researchers working in the field of neuroscience and pharmacology as well as clinicians (pharmacists, radiologists, psychiatrists).
1. Targeted Therapy for the Central Nervous System - p. iii 2. Cover - p. iii 3. Title Page - p. iii 4. Copyright Page - p. iv 5. Table of Contents - p. iv 6. Dedication - p. v 7. Contributors - p. xvii 8. Foreword - p. xxv 9. Preface - p. xxvii 10. Acknowledgments - p. xxix 11. Unveiling new frontiers in treating neurological disorders - p. xxxi 12. Chapter 1 Etiology and treatment challenges for neurodegenerative disorders - p. 1 13. Chapter 2 Etiology and treatment challenges for neurotraumatic and psychiatric disorders - p. 27 14. Chapter 3 Barriers to progress of neurotherapeutics: Getting drugs to the brain - p. 43 15. Chapter 4 IGF-II conjugated nanocarrier for brain targeting - p. 61 16. Chapter 5 ApoE potential in CNS drugs targeting and as CNS therapeutic - p. 79 17. Chapter 6 Transferrin functionalized nanoparticles for targeted drug delivery in biological systems - p. 99 18. Chapter 7 Surface engineered multimodal magnetic nanoparticles for neurodegenerative diseases - p. 121 19. Chapter 8 Tau targeting biomimetic nanoparticles - p. 155 20. Chapter 9 Stem cell therapy as a novel concept to combat CNS disorders - p. 175 21. Chapter 10 SR-B1 receptor targeting in CNS disorders - p. 207 22. Chapter 11 β- and γ-secretases as therapeutic targets for Alzheimer's disease - p. 239 23. Chapter 12 Minimally invasive nasal depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain - p. 265 24. Chapter 13 Immunosuppressive and immunomodulatory therapies - p. 285 25. Chapter 14 CRISPR/Cas9 gene editing: A new hope for Alzheimer's disease - p. 301 26. Chapter 15 Artificial intelligence: Ways and means for central nervous system (CNS) delivery - p. 325 27. Chapter 16 Carbon dots as versatile nano-architectures for the treatment of neurological disorders - p. 349 28. Chapter 17 Animal models for clinical evaluation - p. 369 29. Chapter 18 Medical device: Development of next-generation devices from an engineering perspective - p. 405 30. Chapter 19 Regulation of nanomaterials and nanomedicines for clinical applications - p. 423 31. Chapter 20 Regulatory considerations for the use of biomarkers and personalized medicine in CNS drug development - p. 441 32. Chapter 21 Regulatory toxicology testing for pharmaceuticals - p. 475 33. Chapter 22 Emerging challenges and opportunities for drug and drug product registrations - p. 501 34. Chapter 23 CRISPR/Cas9 gene editing: A new hope for Parkinson's disease - p. 527 35. Index - p. 567
Targeted Therapy for the Central Nervous System: Formulation, Clinical Challenges, and Regulatory Strategies presents research on various delivery methods of drugs to the central nervous system and brain. This volume examines targeted therapies for neurodegenerative disorders and succinctly outlines the future of drug delivery systems, highlighting significant advancements specifically relating to central nervous system delivery. This book will be of great interest to researchers working in the field of neuroscience and pharmacology as well as clinicians (pharmacists, radiologists, psychiatrists).
1. Targeted Therapy for the Central Nervous System - p. iii 2. Cover - p. iii 3. Title Page - p. iii 4. Copyright Page - p. iv 5. Table of Contents - p. iv 6. Dedication - p. v 7. Contributors - p. xvii 8. Foreword - p. xxv 9. Preface - p. xxvii 10. Acknowledgments - p. xxix 11. Unveiling new frontiers in treating neurological disorders - p. xxxi 12. Chapter 1 Etiology and treatment challenges for neurodegenerative disorders - p. 1 13. Chapter 2 Etiology and treatment challenges for neurotraumatic and psychiatric disorders - p. 27 14. Chapter 3 Barriers to progress of neurotherapeutics: Getting drugs to the brain - p. 43 15. Chapter 4 IGF-II conjugated nanocarrier for brain targeting - p. 61 16. Chapter 5 ApoE potential in CNS drugs targeting and as CNS therapeutic - p. 79 17. Chapter 6 Transferrin functionalized nanoparticles for targeted drug delivery in biological systems - p. 99 18. Chapter 7 Surface engineered multimodal magnetic nanoparticles for neurodegenerative diseases - p. 121 19. Chapter 8 Tau targeting biomimetic nanoparticles - p. 155 20. Chapter 9 Stem cell therapy as a novel concept to combat CNS disorders - p. 175 21. Chapter 10 SR-B1 receptor targeting in CNS disorders - p. 207 22. Chapter 11 β- and γ-secretases as therapeutic targets for Alzheimer's disease - p. 239 23. Chapter 12 Minimally invasive nasal depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain - p. 265 24. Chapter 13 Immunosuppressive and immunomodulatory therapies - p. 285 25. Chapter 14 CRISPR/Cas9 gene editing: A new hope for Alzheimer's disease - p. 301 26. Chapter 15 Artificial intelligence: Ways and means for central nervous system (CNS) delivery - p. 325 27. Chapter 16 Carbon dots as versatile nano-architectures for the treatment of neurological disorders - p. 349 28. Chapter 17 Animal models for clinical evaluation - p. 369 29. Chapter 18 Medical device: Development of next-generation devices from an engineering perspective - p. 405 30. Chapter 19 Regulation of nanomaterials and nanomedicines for clinical applications - p. 423 31. Chapter 20 Regulatory considerations for the use of biomarkers and personalized medicine in CNS drug development - p. 441 32. Chapter 21 Regulatory toxicology testing for pharmaceuticals - p. 475 33. Chapter 22 Emerging challenges and opportunities for drug and drug product registrations - p. 501 34. Chapter 23 CRISPR/Cas9 gene editing: A new hope for Parkinson's disease - p. 527 35. Index - p. 567
